Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 17/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4457218 | 0.85 | CNR1 (1.00) | CNR1 | |
| SCHEMBL5162699 | 0.75 | CNR1 (0.66) | CNR1RXFP1 | |
| SCHEMBL5943309 | 0.74 | CNR1 (0.80) | CNR1 | |
| SCHEMBL5943307 | 0.74 | CNR1 (0.80) | CNR1 | |
| SCHEMBL4252470 | 0.73 | CNR1 (0.58) | CNR1 | |
| SCHEMBL4455038 | 0.72 | CNR1 (1.00) | CNR1 | |
| SCHEMBL4456100 | 0.72 | CNR1 (1.00) | CNR1 | |
| SCHEMBL5768879 | 0.72 | CNR1 (0.79) | CNR1 | |
| SCHEMBL5768883 | 0.72 | CNR1 (0.79) | CNR1 | |
| SCHEMBL5768876 | 0.72 | CNR1 (0.79) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156616-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| EP-1910304-A2 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010222-A2 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156616-A1 | THERAPEUTIC AGENTS | NLN, BDNF, GAP43 | CNR1 173/4885TP53 4824/4885MDM2 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.